A study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Trial Identifier: D8220C00018
Sponsor: AstraZeneca
Collaborator:
Acerta Pharma
NCTID:: NCT04488016
Start Date: June 2020
Primary Completion Date: January 2021
Study Completion Date: January 2021
Condition: Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version

Trial Locations

Country Location
United States of America, MD Baltimore, MD, United States of America, 21225